生命科学研究2017，Vol.21Issue(4)：349-354,6.DOI:10.16605/j.cnki.1007-7847.2017.04.012
Daratumumab靶向治疗多发性骨髓瘤的研究进展
Research Progresses of Daratumumab Targeted Treatment for Multiple Myeloma
摘要
Abstract
Multiple myeloma (MM) is a malignant clonal disease that is characterized by proliferation of plasma cells in the bone marrow.Although the therapy for MM has made great process in recent years,it remains an incurable disease.Daratumumab (DARA) is a humanized monoclonal antibody that targets CD38 with broad-spectrum killing activity.Recent studies have shown that DARA induces rapid MM cell death via several mechanisms.Here,the CD38 molecule and DARA as a single agent or in combination with other agents in the treatment of relapsed/refractory MM in preclinical experiments and clinical trials were reviewed to show the mechanisms of DARA in inducing rapid death of MM cells and the efficacy and safety of DARA in the treatment of relapsed/refractory MM patients.It may provide new research directions in the treatment of relapsed/refractory MM patients with DARA.关键词
多发性骨髓瘤(MM)/单克隆抗体药物/daratumumab (DARA)/CD38分子Key words
multiple myeloma (MM)/monoclonal antibody drug/daratumumab (DARA)/CD38分类
生物科学引用本文复制引用
吴婷,吴文芳,邓梅春..Daratumumab靶向治疗多发性骨髓瘤的研究进展[J].生命科学研究,2017,21(4):349-354,6.基金项目
国家自然科学基金资助项目(31672290,31100764) （31672290,31100764）
中国博士后科学基金资助项目(2012M521536) （2012M521536）
湖南省自然科学基金资助项目(2016JJ3180) （2016JJ3180）
